4-methyl-4-methylsulfanylpentan-2-one

We are 4-methyl-4-methylsulfanylpentan-2-one CAS:23550-40-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-methyl-4-methylsulfanylpentan-2-one
CAS.NO:23550-40-5
Synonyms:4-methyl-4-methylsulfanylpentan-2-one
4-methyl-4-methylsulfanyl-pentan-2-one
4-Methylthio-4-methyl-2-pentanone
 
Physical and Chemical Properties:
Density 0.9±0.1 g/cm3
Boiling Point 202.4±23.0 °C at 760 mmHg
Molecular Formula C7H14OS
Molecular Weight 146.251
Flash Point 73.5±8.3 °C
 
Specification:
Appearance:Colorless to pale yellow transparent liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Flavors and fragrances intermediate

4-methyl-4-methylsulfanylpentan-2-one


Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.2,3,4,5,6-Pentafluorostyrene CAS:653-34-9 In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.6139-83-9 In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.447-61-0 In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.

Related Products
Product Name
1-bromobut-2-yne View Details
2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzonitrile View Details
(aminomethyl)phosphonic acid View Details
2-Amino-5-cyanobenzotrifluoride manufacturer 3′-Amino-2′-hydroxyacetophenone hydrochloride manufacturer 2-phenyl-1H-pyridazine-3,6-dione manufacturer 3-chloropropoxymethylbenzene manufacturer 4-fluorobutyl acetate manufacturer